middle.news
How Artrya’s FDA Clearance Fuels Its U.S. Launch Amid Rising Losses
8:48pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
How Artrya’s FDA Clearance Fuels Its U.S. Launch Amid Rising Losses
8:48pm on Friday 29th of August, 2025 AEST
Key Points
Net loss increased 17.2% to $16.4 million for year ended June 2025
FDA 510(k) clearance received for Salix Coronary Anatomy platform
U.S. commercial launch initiated with Tanner Health and other hospital partners
Australian partnerships secured with Sonic Healthcare and Lumus Imaging
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Artrya (ASX:AYA)
OPEN ARTICLE